GH Research is an Irish biopharmaceutical company founded in 2018 that is seeking an “ultra-rapid” treatment for depression. GH is currently developing two 5-MeO-DMT products. The first is a 5-MeO-DMT inhalant targeting treatment-resistant depression. The second is a pre-clinical 5-MeO-DMT injectable intended to treat psychiatric and neurological disorders.
5-MeO-DMT is a serotonergic tryptamine whose clinical potential is supported by emergent literature. One study by Dr. Roland Griffith’s team at Johns Hopkins found that the substance had significant antidepressant and anxiolytic effects (read a summary of the study by Psychedelic Science Review here).1 Another study by the team found that “mystical-type experiences with enduring positive effects” occasioned by inhaled 5-MeO-DMT “are more intense when 5-MeO-DMT is administered in a safe and supportive context.”2 Another Psychedelic Science Review article discussed their findings.
GH concluded Phase 1 clinical trials of its inhalant in healthy volunteers in Spring 2021. As of Summer 2021, its Phase 2 studies in patients with treatment-resistant depression are in progress.3
GH began trading publicly on NASDAQ in Summer 2021. The company’s advisors include Professor Dr. Johannes Ramaekers of Maastricht University.